Connect to other sites within the UBM Medica Network
Genetics May Explain Aggressive Breast Tumors in African Americans
According to the results of a genomic analysis, several genetic characteristics linked with aggressive cancer are more common in the breast tumors of African American women compared to their white counterparts.
Bone-Seeking Radionuclides Provide Pain Relief for Prostate Cancer Bone Mets
The use of bone-seeking radionuclides effectively controlled bone pain in men with prostate cancer metastatic to the bone, according to the results of a systematic review.
Routine Imaging Not Necessary Part of DLBCL Follow-Up Post Remission
Patients who are in complete remission from diffuse large B-cell lymphoma may not need to undergo routine imaging follow-up, a new study showed.
Marker in Thyroid Cancer Can Help Reclassify Patients as Low Risk
Papillary thyroid cancer patients at intermediate risk according to guidelines can be reclassified as low risk when postoperative stimulated thyroglobulin is low.
Pain Flare Occurs in 4 of 10 Patients After RT for Bone Metastases
Almost 40% of patients undergoing palliative radiotherapy to treat symptomatic bone metastases experienced pain flare, according to an observational study.
New CML Risk Score Incorporates Modern Survival Probability
A new risk assessment score more accurately reflects the probability of dying from chronic myeloid leukemia than do existing scoring systems.
Five New Risk Loci Identified for Gliomas
A new genetic analysis found five new genetic variants that raise the risk for gliomas. One of the five was associated with a sharply increased risk for glioblastoma.
Ibrutinib Improves on Standard of Care in CLL/SLL
A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.
Adjuvant Chemo Ups Survival in High-Risk Localized Prostate Cancer
The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.
Palbociclib, Fulvestrant Delays HR-Positive Breast Cancer Progression
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
Anastrozole Trumps Tamoxifen in DCIS
Treatment of postmenopausal DCIS patients with the aromatase inhibitor anastrozole resulted in higher breast cancer–free survival rates compared with treatment with tamoxifen.
By clicking Accept, you agree to become a member of the UBM Medica Community.